Table 2.

Summary of recent new drug candidates in sepsis.

Drugs	Structure	Dosage	Mechanism	Ref.
MEDI4893	Human immunoglobulin	225, 750, 2250, 5000 mg	Binds S. aureus alpha toxin with a high affinity	[94]
MEDI3902	Human immunoglobulin	250, 750, 1500 or 3000 mg, i.v.drip	Bind to both the PcrV protein and Psl exopolysaccharide on the surface of P. aeruginosa	[95]
ART-123	Human soluble thrombomodulin	0.06 – 6 mg/kg/d, i.v.drip	Change thrombin substrate specificity from pro-coagulant to anti-coagulant activity through the activation of protein C	[96]
Adrenomedullin	Short half-life free circulating peptide	2, 4 mg/kg, i.v.drip	Reinforce the endothelial barrier and reduce sepsis-induced vascular leakage	[97]
GM-CSF	Recombinant human granulocyte-macrophage colony-stimulating factor	4 μg/kg/day, i.c.	Stimulate the production, maturation, and function of monocytes/macrophages and neutrophils	[98]
Nangibotide	Synthetic TREM-1 antagonistic peptide	0.3, 1.0, 3.0 mg/kg/h, i.v.drip	Decrease leukocyte activation and innate immune response	[99]
CYT-107	Pluripotent cytokine	10 μg/kg, once a week or twice a week	Reverse sepsis-induced lymphopenia and avoid excessive inflammatory response	[100]